Bioequivalence Study of Ribavirin in Healthy Adult Subjects Under Fed Condition
Status:
Completed
Trial end date:
2020-11-23
Target enrollment:
Participant gender:
Summary
To evaluate and compare the relative plasma bioavailability and therefore the bioequivalence
of two different immediate release products each containing Ribavirin 400 mg, after
administering a single oral dose, to healthy adult subjects under fed conditions.